Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals, Inc. reports developments in clinical-stage oncology focused on azenosertib, an investigational WEE1 inhibitor being developed as a biomarker-driven treatment approach for ovarian cancer. Company updates commonly address Cyclin E1-positive platinum-resistant ovarian cancer, the DENALI, ASPENOVA and MUIR clinical programs, and scientific presentations involving ovarian cancer and triple-negative breast cancer research.
ZNTL news also includes financial results and operational updates, FDA-related clinical and regulatory disclosures, equity inducement grants under Nasdaq rules, and governance matters tied to the company’s public-company status.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) closed its previously announced underwritten public offering of 26,450,000 common shares, including 3,450,000 from the underwriters’ fully exercised option. Shares were priced at $3.50, generating approximately $92.6 million in gross proceeds before fees and expenses.
According to the company, all shares were issued by Zentalis. The company plans to use net proceeds, together with existing cash and marketable securities, to fund clinical trials, preclinical studies, regulatory filings, manufacturing, companion diagnostic work, pre-commercial activities, capital expenditures, working capital and other general corporate purposes.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) priced an underwritten public offering of 23,000,000 common shares at $3.50 per share, for expected gross proceeds of approximately $80.5 million before fees. All shares are offered by the company, with closing expected on August 17, 2026, subject to customary conditions.
Zentalis granted underwriters a 30-day option to purchase up to 3,450,000 additional shares at the public offering price, less discounts and commissions. According to Zentalis, net proceeds plus existing cash will fund clinical and preclinical work, regulatory filings, manufacturing, companion diagnostics, pre-commercial activities, and general corporate purposes.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has commenced a proposed underwritten public offering of common stock and, for certain investors, pre-funded warrants as an alternative to common shares. All securities will be issued and sold by the company, which expects to grant underwriters a 30-day option to purchase up to an additional 15% of common shares on the same terms.
According to Zentalis, net proceeds, combined with existing cash and marketable securities, are intended to fund clinical and preclinical development of its WEE1 inhibitor azenosertib and other programs, regulatory filings, manufacturing, companion diagnostic work, pre-commercial activities, capital expenditures, working capital and general corporate purposes. TD Cowen, Guggenheim Securities and Oppenheimer & Co. are joint bookrunners. The offering will be made under an effective SEC shelf registration statement.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) reported second quarter 2026 results and clinical updates centered on its investigational WEE1 inhibitor azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). Following a Type D FDA meeting, the agency raised no objections to the continued study of the 400mg QD 5:2 monotherapy dose and acknowledged that the DENALI Part 2 population, including Part 2c, may support an accelerated approval pathway, subject to data strength and future treatment landscape.
Enrollment in DENALI Parts 2a and 2b is complete and Part 2c is enrolling, with an integrated topline readout expected in 1H 2027. The ASPENOVA Phase 3 confirmatory trial has dosed its first patient and is enrolling approximately 420 patients. The company reported cash, cash equivalents and marketable securities of $174.6 million as of June 30, 2026, which it believes will fund operations into late 2027. Second quarter 2026 research and development expenses were $35.2 million, total operating expenses were $44.4 million, and net loss was $42.3 million, or $0.59 per share.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) reported that on August 3, 2026, its Board Compensation Committee granted non-qualified stock options to purchase an aggregate 84,000 shares of common stock to two newly hired employees under its 2022 Employment Inducement Incentive Award Plan.
The options were issued as material inducement awards in accordance with Nasdaq Listing Rule 5635(c)(4), carry a $4.65 exercise price equal to the grant-date closing price, have a 10-year term, and vest over four years: 25% after one year and the remaining 75% in equal monthly installments over the following three years, subject to continued service.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) will deliver two presentations on its investigational WEE1 inhibitor azenosertib at the ESMO Congress 2026 in Madrid, Spain, on October 23-27, 2026. A rapid oral session will share overall survival data from Part 1b of the Phase 2 DENALI study in platinum-resistant ovarian cancer (PROC).
Zentalis will also present a trial-in-progress poster on ASPENOVA, a Phase 3 randomized study comparing azenosertib monotherapy at 400mg QD 5:2 to standard single-agent chemotherapy in Cyclin E1-positive PROC, designed to support potential accelerated and full approval pathways.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) granted non-qualified stock options to purchase an aggregate of 191,000 shares of common stock to two newly hired employees on June 1, 2026.
The options, issued under the 2022 Employment Inducement Incentive Award Plan, have a $3.98 exercise price, 10-year term, and four-year vesting schedule.
Zentalis (Nasdaq: ZNTL) appointed Shannon Campbell to its Board of Directors and Sarah Kelly as Senior Vice President of Commercial Strategy.
These moves support commercialization readiness as Zentalis advances its registrational program for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer, including the Phase 2 DENALI and Phase 3 ASPENOVA trials.
Zentalis (Nasdaq: ZNTL) reported Part 1 data from the Phase 1b MUIR trial of azenosertib plus paclitaxel in platinum-resistant ovarian cancer.
In 46 all-comer patients, the regimen showed 39.1% ORR, 7.3-month median PFS, and a manageable safety profile, with a 50% ORR in the 250 mg 5:2 cohort.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced management will participate in multiple investor conferences in May and June 2026, featuring fireside discussions.
Events include H.C. Wainwright, Stifel, TD Cowen, and Jefferies, with live and archived webcasts accessible via the company’s Investors & Media website section.